



# argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025

**May 1, 2025**

**Amsterdam, the Netherlands** – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 8, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its first quarter 2025 financial results and provide a business update.

A webcast of the live call may be accessed on the Investors section of the argenx website at [argenx.com/investors](https://www.argenx.com/investors). A replay of the webcast will be available on the argenx website for approximately one year following the presentation.

Dial-in numbers:

Belgium	32 800 50 201
France	33 800 943355
Netherlands	31 20 795 1090
United Kingdom	44 800 358 0970
United States	1 888 415 4250
Japan	81 3 4578 9081
Switzerland	41 43 210 11 32

*Use the access code 3810049 to join the call. Please dial in 15 minutes prior to the live call.*

## About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit [www.argenx.com](https://www.argenx.com) and follow us on [LinkedIn](#), [Instagram](#), [Facebook](#), and [YouTube](#).

## Contacts

### Media:

Ben Petok  
[bpetok@argenx.com](mailto:bpetok@argenx.com)

### Investors:

Alexandra Roy  
[aroy@argenx.com](mailto:aroy@argenx.com)